Single-tablet pioglitazone combination filed in Japan
This article was originally published in Scrip
Executive Summary
Takedahas filed an approval submission in Japan for a single-tablet combination of pioglitazone and metformin. The product stands to become the first fixed dose combination for type 2 diabetes in Japan, where pioglitazone, a thiazolidinedione, is already marketed alone as Actos. The single-tablet combination was approved as Actoplus met in the US this August and approved in the EU (as Competact) in July 2007. Japanese filings for Actos as concomitant therapy with either metformin or insulin were made in January and June respectively last year.
You may also be interested in...
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Teva’s immunology biosimilar launches; Intra-Cellular’s promising depression data; Phase III sleep apnea win for Lilly’s tirzepatide; an interview with Viking’s CEO; and China looks to define innovative drugs.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.